Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes.

BACKGROUND: ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may have anti-tumor properties. We investigated whether the use of ACEI/ARBs affects the clinical outcomes of primary breast cancer patients receiving taxane and anthracycline-based neoadjuvant chemotherapy.
METHODS: We included 1449 patients with diagnosis of invasive primary breast cancer diagnosed at the MD Anderson Cancer Center between 1995 and 2007 who underwent neoadjuvant chemotherapy. Of them, 160 (11%) patients were identified by review of their medical record, as ACEI/ARBs users. We compared pathologic complete response (pCR) rates, relapse-free survival (RFS), disease-specific survival (DSS) and overall survival (OS) between ACEI/ARB users and non-users. Descriptive statistics and Cox proportional hazards model were used in the analyses.
RESULTS: There was no difference in the pCR rates between ACEI/ARB users and non-users (16% vs 18.1%, p-=0.50). After adjustment for important demographic and clinical characteristics, no significant differences between ACEI/ARB users and nonusers were observed in RFS (HR=0.81; 95% CI=0.54-1.21), DSS (HR=0.83; 95% CI=0.52-1.31), or OS (HR=0.91; 95% CI =0.61-1.37). In a subgroup analysis, the 5-year RFS was 82% in ARB only users versus 71% in ACEI/ARB non-users (P=0.03). In the multivariable analysis, ARB use was also associated with a decreased risk of recurrence (HR=0.35; 95% CI=0.14-0.86). No statistically significant differences in DSS or OS were seen.
CONCLUSION: No differences in pCR and survival outcomes were seen between ACEI/ARB users and non-users among breast cancer patients receiving neoadjuvant chemotherapy. ARB use may be associated with improved RFS. Further research is needed to validate this finding.

Introduction

The renin angiotensin system (RAS) is a peptide based homeostatic gatekeeper system known to play a role in blood pressure control and electrolyte balance1, 2. ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are the two widely used RAS antagonists. They inhibit the effect of angiotensin II, and they are used in the treatment of hypertension, congestive heart failure, and diabetic nephropathy. There is a growing body of evidence to suggest that ACEIs might have anti-tumor properties2, 3. Angiotensin II is now regarded as a tumor growth promoter via angiogenesis from activation of the VEGF pathway4-6. In animal studies, ACEI administration has led to decreased neo-vascularization and VEGF levels7, 8. ACEIs have also demonstrated anti-inflammatory and pro-apoptotic activity via the NF kappa B and apoptosis pathways, respectively2, 3. In addition, although still controversial, epidemiologic studies have found that the use of ACEIs was associated with decreased risk of developing cancers including solid and skin cancers9-12.

Breast cancer is the second most common cause of cancer-related mortality among women in the US13. Breast cancer was shown to express full components of the RAS14. Angiotensin II acts as a growth factor both in normal and cancer breast epithelial cells and promotes adhesion and invasion15, 16. AGTR1, a gene encoding angiotensin receptor type 1, was found to be markedly expressed in 10-20% of human breast cancer tissues, mutually exclusive with ERBB2 overexpression. Furthermore, the ectopic expression of AGTR1 in primary mammary epithelial cells combined with angiotensin II stimulation induced cell proliferation later attenuated by the ARB17.

Neoadjuvant systemic therapy (NST) is part of the standard treatment for locally advanced and inflammatory breast cancer, and it is increasingly used in earlier stage disease. NST produces downstaging of the disease leading to better surgical resectability while assessing the efficacy of the chemotherapy regimen. Achieving a pathologic complete response (pCR) is an independent surrogate marker for better long-term outcome18-22. The purpose of our study was to determine whether the use of RAS antagonists affected the clinical outcome of primary breast cancer patients receiving NST.

Methods

Patient population

From a prospectively maintained database in the Breast Medical Oncology department at The University of Texas MD Anderson Cancer Center, we identified patients receiving NST. We included a total of 1449 patients with diagnosis of invasive breast cancer between 1995 and 2007 treated with anthracycline and taxane-based NST. We excluded patients with metastatic disease at the time of diagnosis, patients with bilateral disease, or male breast cancer patients. We collected demographic variables, tumor characteristics (histology; grade; lymphovascular invasion [LVI]; estrogen receptor [ER]; progesterone receptor [PR]; and human epidermal growth factor receptor 2 [HER2] status), clinical stage at diagnosis (according to the American Joint Committee on Cancer Criteria, 6th edition23), body mass index (BMI), pathological stage, and recurrence and survival information. Patients treated with ACEI/ARBs while on NST were identified by chart and pharmacy medication record review. The type of ACEIs or ARBs and other medications that may affect pCR and relapse (beta-blocker, metformin) were also collected as we previously reported24-27. Patients were followed according to current practice guidelines28. The institutional review board of our institution approved the retrospective review of the medical records for the purpose of this study.

Pathology

All pathologic specimens were reviewed by dedicated breast pathologists. The histology, grade, pathologic stage, and analysis of ER, PR, and HER2 status were classified as previously described29. All surgical breast and axillary lymph node specimens were reviewed to identify the presence of residual disease. pCR was defined as no evidence of invasive carcinoma in the breast and axillary lymph nodes at time of surgery25.

Treatment

All patients received NST with anthracycline (doxorubicin, epirubicin) and taxane (paclitaxel, docetaxel) based regimen. Detailed chemotherapy regimens are decribed in our early studies24-26. At the completion of NST, every patient underwent definitive surgery. Axillary lymph node staging with axillary lymph node dissection or sentinel lymph node biopsy was performed on all patients. Adjuvant hormonal therapy and/or trastuzumab treatment was administered according to standard practice28. Trastuzumab was not used in the neoadjuvant setting. Radiation was delivered when patients underwent breast conservation surgery or had locally advanced disease; a primary tumor measuring > 5 cm, or ≥ 4 involved lymph nodes.

Statistical analysis

Patient characteristics were compared according to whether patients received ACEIs/ARBs. Survival analyses were performed to compare the relapse-free survival (RFS), disease-specific survival (DSS) and overall survival (OS) between groups. RFS was defined from the date of diagnosis to the date of first documented local or distant recurrence or last follow-up. Patients who died before experiencing disease recurrence were censored at their date of death. DSS was measured from the date of diagnosis to the date of death from disease or last follow-up. OS was calculated from the date of diagnosis to the date of death from any cause or last follow-up. The Kaplan-Meier method was used to estimate the survival outcomes. A multivariable logistic regression model was fit to examine the relation between the use of ACEI/ARBs and pCR. Variables in the model included age, stage of disease, tumor grade, tumor subtype, LVI, and BMI. We also included the use of metformin and beta-blockers as covariates in the model based on our prior findings24, 26. Cox proportional hazards models were fitted to determine the association of ACEi/ARBs use with survival outcomes after adjustment for other patient and clinical characteristics. Subset analyses were carried out within each of the three subtype groups: hormonal receptor positive, HER2 positive and triple receptor negative. Statistical analyses were performed using SAS (version 9.1; SAS Institute Inc, Cary, NC) and S-Plus 7.0 (Insightful Corporation, Seattle, Wash) statistical software. P values<0.05 were considered to be statistically significant, all tests were two sided.

Results

ACE inhibitors and/or ARBs with pCR Rates

Among 1449 breast cancer patients, 160 (11%) used ACEI/ARBs while they were treated with NST and 1289 (89%) patients did not. Among the ACEI/ARB-treated patients, 105 (65%) were on ACEIs and 54 (34%) were on ARBs. Commonly used ACEIs were lisinopril (31.4%), enalapril (19.0%), and benazepril (17.1%); commonly used ARBs were valsartan (37.0%), irbesartan (22.0%), and losartan (22.0%). Patient characteristics are summarized in Table 1. Patients in the ACEI/ARB group were older than those in the non-ACEI/ARB group (P<0.001), and consequently this group had a higher proportion of postmenopausal patients (P<0.001). Fifty-three percent of the patients in the ACEI/ARB group were obese versus 32% in the non-ACEI/ARB group (P<0.001). Twenty-three percent of the black patients versus 14% of the non-black patients took ACEI/ARB (P=0.002). Thirteen percent of the patients in the ACEI/ARB group used metformin versus 2% in the non-ACEI/ARB group (P<0.001). Twenty-nine percent of the patients in the ACEI/ARB group used beta-blockers versus 4.9% in the non-ACEI/ARB group (P<0.001). The other prognostic factors were not significantly different between the two groups.

Table 1

Patient Characteristics by ACE inhibitors/ARBs

	Non- ACEI/ARB(N=1289)		ACEI/ARB (N=160)
	N	%	N	%	P
Age, Median	48		58
Age
< 50	701	54.4	27	16.9
≥ 50	588	45.6	133	83.1	< 0.001
Menopausal Status
Pre	655	50.9	25	15.6
Post	631	49.1	135	84.4	< 0.001
Body Mass Index
Normal/underweight	447	35.9	25	15.8
Overweight	404	32.4	49	31.0
Obese	394	31.6	84	53.2	< 0.001
Race
White/Other	1115	86.5	124	77.5
Black	174	13.5	36	22.5	0.002
Clinical Stage
I	55	4.3	3	1.9
II	700	54.5	86	54.1
III	530	41.2	70	44.0	0.32
Nuclear Grade
I	47	3.8	4	2.6
II	417	33.3	44	28.4
III	788	62.9	107	69.0	0.31
LVI
Negative	850	68.4	112	72.3
Positive	393	31.6	43	27.7	0.33
Subtype
HR- positive	705	55.4	86	54.1
HER2 positive	231	18.1	27	17.0	0.79
Triple negative	337	26.5	46	28.9
Metformin Use
No	1269	98.4	140	87.5
Yes	20	1.6	20	12.5	< 0.001
Beta-blocker Use
No	1211	95.1	100	71.4
Yes	62	4.9	40	28.6	< 0.001

Abbreviations: ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor antagonist; LVI, lymphovascular invasion; HER-2, human epidermal growth factor receptor 2; HR, hormone receptor.

There was no difference in the estimates of pCR rates between ACEI/ARB and non-ACEI/ARB groups. The proportion of pCR was 16% (95%CI 14%-18.1%) in the non-ACEI/ARB group and 18.1% (95%CI 12.2%-24.1%) in the ACEI/ARB group (P=0.50). The use of ACEI/ARBs was not an independent predictor of pCR (OR= 1.30; 95%CI 0.79-2.13). Table 2 shows the multivariate logistic regression models. When the same analyses were done for ACEI (n=105) and ARB (n=54) users separately, the results were similar.

Table 2

Multivariate Logistic Regression Model for ACE inhibitors/ARBs on pCR among All Patients

	Odds Ratio	95% CI	P		Adjusted Odds Ratio	95% CI	P
ACEI/ARB use: yes vs. no	1.30	0.79 to 2.13	0.3		1.44	0.84 to 2.48	0.18
Age: ≥ 50 vs. < 50	0.67	0.48 to 0.93	0.018		0.66	0.47 to 0.93	0.018
BMI: overweight vs. normal	0.68	0.45 to 1.01	0.022		0.69	0.46 to 1.04	0.021
BMI: obese vs. normal	1.04	0.71 to 1.52	0.16		1.10	0.75 to 1.63	0.1
Stage: III vs. I/II	0.69	0.49 to 0.95	0.025		0.70	0.5 to 0.98	0.036
Grade: III vs. I/II	3.69	2.31 to 5.89	<.001		3.42	2.14 to 5.48	<.001
LVI: positive vs. negative	0.39	0.26 to 0.57	<.001		0.37	0.25 to 0.56	<.001
Subtype: HER2 positive vs. HR positive	3.06	1.99 to 4.69	<.001		3.18	2.05 to 4.93	<.001
Subtype: Triple negative vs. HR positive	2.65	1.8 to 3.92	0.012		2.78	1.87 to 4.14	0.009
Metformin use: yes v. no					0.66	0.21 to 2.1	0.48
Beta-blocker use: yes v. no					0.84	0.43 to 1.62	0.59

Abbreviations: ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor antagonist; pCR, pathologic complete response; HR: hormonal receptor; LVI, lymphovascular invasion; BMI, body mass index; CI, confidence interval

ACE inhibitors and / or ARBs with Survival Outcomes

Patients stratified by ACE inhibitors/ARBs

The median follow up was 55 months (range 3-145 months). The survival outcomes according to ACEI/ARB use are listed in Table 3. There were 415 recurrences, 312 disease-specific deaths and 359 deaths. No differences in RFS (P=0.47), DSS (P=0.67), or OS (P=0.35) were observed (Figure 1A). In the multivariable model shown in Table 4 no differences in RFS (HR=0.81; 95%CI 0.54-1.21), DSS (HR=0.83; 95%CI 0.52-1.31), or OS (HR=0.91; 95%CI 0.61-1.37) were seen after adjusting for age, race, BMI, stage, grade, LIV, subtype, metformin and beta-blocker use.

Table 3

Five-year Survival Estimates by Patient and Clinical Characteristics among All Patients

		Recurrence-Free Survival				Disease-Specific Survival					Overall Survival
	N Patients	N Events	5-YearEstimate(95% CI)	P		N Events	5-YearEstimates(95% CI)	P		N Events	5-YearEstimates(95% CI)	P
All	1449	415	0.71(0.68, 0.73)			312	0.79(0.77, 0.82)			359	0.77(0.74, 0.79)
ACEI/ARB
No	1289	374	0.71(0.68, 0.73)			277	0.8(0.77, 0.82)			316	0.77(0.74, 0.8)
Yes	160	41	0.73(0.64, 0.79)	0.47		35	0.79(0.71, 0.85)	0.67		43	0.76(0.68, 0.82)	0.35
ACEI
Non-ACEI/ARB	1289	374	0.71(0.68, 0.73)			277	0.8(0.77, 0.82)			316	0.77(0.74, 0.8)
ACEI	105	33	0.67(0.56, 0.76)	0.46		30	0.71(0.6, 0.8)	0.05		35	0.69(0.58, 0.78)	0.03
ARBs
Non-ACEI/ARB	1289	374	0.71(0.68, 0.73)			277	0.8(0.77, 0.82)			316	0.77(0.74, 0.8)
ARB	54	8	0.82(0.66, 0.91)	0.03		5	0.92(0.81, 0.97)	0.06		8	0.89(0.77, 0.95)	0.16
Hormone Receptor Positive	791	178	0.77(0.73, 0.8)			126	0.86(0.83, 0.88)			149	0.84(0.81, 0.87)
Non-ACEI/ARB	705	159	0.77(0.73, 0.8)			111	0.86(0.83, 0.89)			130	0.84(0.81, 0.87)
ACEI/ARB	86	19	0.77(0.65, 0.85)	0.96		15	0.84(0.74, 0.91)	0.47		19	0.82(0.72, 0.89)	0.25
ACEI	58	16	0.73(0.59, 0.83)	0.34		14	0.79(0.64, 0.88)	0.08		17	0.77(0.63, 0.86)	0.04
ARB	27	3	0.83(0.55, 0.94)	0.20		1	0.96(0.75, 0.99)	0.17		2	0.92(0.73, 0.98)	0.28
HER2 Positive	258	92	0.66(0.59, 0.72)			62	0.81(0.75, 0.85)			70	0.78(0.72, 0.83)
Non-ACEI/ARB	231	85	0.65(0.58, 0.71)			57	0.8(0.74, 0.85)			63	0.78(0.72, 0.83)
ACEI/ARB	27	7	0.73(0.51, 0.86)	0.29		5	0.88(0.68, 0.96)	0.46		7	0.81(0.61, 0.92)	0.80
ACEI	16	5	0.66(0.37, 0.85)	0.80		4	0.79(0.48, 0.93)	0.91		6	0.68(0.4, 0.86)	0.39
ARB	11	2	0.82(0.45, 0.95)	0.19		1	1	0.21		1	1	0.18
Triple Negative	383	140	0.63(0.57, 0.68)			121	0.64(0.59, 0.7)			136	0.61(0.55, 0.66)
Non-ACEI/ARB	337	125	0.62(0.57, 0.68)			106	0.65(0.59, 0.7)			119	0.61(0.55, 0.67)
ACEI/ARB	46	15	0.65(0.49, 0.77)	0.58		15	0.6(0.41, 0.74)	0.71		17	0.58(0.39, 0.73)	0.65
ACEI	30	12	0.56(0.35, 0.72)	0.73		12	0.5(0.27, 0.69)	0.23		12	0.5(0.27, 0.69)	0.40
ARB	16	3	0.81(0.52, 0.94)	0.17		3	0.81(0.51, 0.93)	0.34		5	0.75(0.46, 0.9)	0.74

Abbreviations: LVI, lymphovascular invasion; BMI, body mass index; CI, confidence interval; ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor antagonist

Figure 1

Recurrence free survival, disease specific survival, and overall survival by the use of ACEI/ARBs (A), ACEI only (B), and ARB only (C) among all patients. Abbreviations: ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor antagonist

Table 4

Multivariable Cox Proportional Hazards Model by ACE inhibitors/ARBs for All Patients

	Recurrence-Free Survival				Disease-Specific Survival				Overall Survival
	HR	95% CI	P		HR	95% CI	P		HR	95% CI	P
ACEI/ARB use: yes vs. noAge: ≥ 50 vs. < 50	0.810.92	0.54 to 1.210.74 to 1.14	0.300.46		0.831.03	0.52 to 1.310.8 to 1.32	0.420.82		0.911.16	0.61 to 1.370.91 to 1.46	0.660.23
Race: black vs. non-black	1.36	1.03 to 1.8	0.029		1.33	0.97 to 1.83	0.08		1.39	1.03 to 1.86	0.03
BMI: overweight vs. normal	1.03	0.79 to 1.33	0.85		1.00	0.74 to 1.36	0.99		1.09	0.82 to 1.46	0.55
BMI: obese vs. normal	1.18	0.91 to 1.53	0.22		1.16	0.85 to 1.57	0.36		1.22	0.91 to 1.63	0.18
Stage: III vs. I/II	1.81	1.46 to 2.24	<.0001		1.95	1.51 to 2.51	<.0001		1.89	1.5 to 2.4	<.0001
Grade: III vs. I/II	1.19	0.91 to 1.54	0.2		1.62	1.17 to 2.25	0.004		1.50	1.11 to 2.03	0.008
LVI: positive vs. negative	1.93	1.56 to 2.39	<.0001		1.67	1.3 to 2.15	<.0001		1.75	1.38 to 2.21	<.0001
Subtype: HER2 positive vs. HR positive	1.57	1.18 to 2.1	0.002		1.17	0.83 to 1.67	0.37		1.12	0.81 to 1.56	0.49
Subtype: Triple negative vs. HR positive	2.01	1.55 to 2.61	<.0001		2.30	1.71 to 3.1	<.0001		2.24	1.7 to 2.96	<.0001
Metformin use: yes v. no	0.98	0.5 to 1.95	0.96		1.36	0.65 to 2.84	0.41		1.07	0.51 to 2.22	0.86
Beta-blocker use: yes v. no	0.51	0.29 to 0.87	0.015		0.51	0.27 to 0.96	0.038		0.63	0.37 to 1.08	0.09
ACEI vs. non-ACEI/ARB *	1.10	0.71 to 1.69	0.68		1.07	0.65 to 1.77	0.79		1.11	0.7 to 1.74	0.66
ARB vs. non-ACEI/ARB *	0.35	0.14 to 0.86	0.022		0.41	0.15 to 1.13	0.08		0.59	0.27 to 1.27	0.17

Abbreviations: ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor antagonist; BMI, body mass index; LVI, lymphovascular invasion; HR, hormonal receptor; HR, hazard ratio; CI, confidence interval, * Separate multivariate analysis done as with ACE/ARB.

Among patients treated exclusively with ACEIs, the 5-year estimate of RFS and DSS was not statistically different from those not using ACEIs. However, OS was inferior in ACEI users compared with non-users (5 year OS rate 69% vs. 77%, p=0.03) (Table 3, Figure 1B). In the multivariable model there was no significant difference between ACE and non-ACEI/ARB-user group in terms of RFS (HR=1.10; 95%CI=0.71-1.69), DSS (HR=1.07; 95%CI=0.65-1.77), or OS (HR=1.11; 95%CI = 0.70-1.74).

Among patients treated exclusively with ARBs, the 5-year estimate of RFS was 82% while it was 71% in the non-ACEI/ARB group (P=0.03); there was no statistically significant difference in the rate of DDS (P=0.06) or OS (P=0.16) (Table 3, Figure 1C). In the multivariable model, ARBs use was associated with a decreased risk of recurrence (HR=0.35; 95%CI=0.14-0.86). There were no significant differences in terms of DSS (HR=0.41; 95%CI=0.15-1.13) or OS (HR=0.59; 95%CI=0.27-1.27).

In a subset analyses according to tumor subtype ACEI use was associated with a worse 5-year OS rate (77% for ACEI versus 84% for non-ACEI/ARB; P=0.04) in patients with hormone receptor-positive tumors. However, after adjustment for potential confounders, the effect of ACEIs was no longer significant (HR=1.14; 95%CI=0.60-2.19). Similar 5-year OS rates were seen among patients with triple-negative and HER2-positive tumors according to ACE/ARB use.

Discussion

The purpose of our study was to assess the effect of ACEI/ARB use on pCR rates and subsequent survival outcomes in patients treated with taxane- and anthracycline- based neoadjuvant chemotherapy. We found that the use of ACEI/ARBs at the time of chemotherapy had no effect on either the pCR rates or survival outcome measures including RFS, DSS and OS. Based on previous reports describing AGTR1 overexpression in hormone receptor positive and HER2-negative tumors1, we explored the effect of ACEI/ARBs according to different tumor subtypes, but no significant differences were observed.

When stratified by ACEIs and ARBs use separately and compared to the non- ACEI/ARB group, we found that ARB use was associated with favorable RFS, there was a trend favoring DSS but there were no differences in OS. Even after controlling for possible confounders, the association remained statistically significant for RFS (HR=0.35, 95%CI=0.14-0.86). ARB use alone has not been previously reported to be associated with decrease risk of breast cancer recurrence. Sensitivity analysis comparing the ACEI group with the non-ACEI group, and the ARB group with the non-ARB group were performed. We found similar results as above indicating that the effect of ARB use may not be from the differences in the control groups (result not shown). The small number of events among ARB users warrants a careful interpretation of this finding.

Previous studies have focused on the association between breast cancer incidence and the use of RAS antagonists rather than cancer progression9-12. Two studies have investigated the association between the use of ACEI/ARBs and breast cancer recurrence30, 31. We reported that use of ACEI/ARBs was associated with reduced risk of recurrence in a retrospective analysis of 703 stage II and III breast cancer patients (HR=0.49; 95%CI=0.31-0.76)30. However, in this study, a similar association was observed in ARB users (HR=0.35; 95%CI=0.14-0.86) and not in ACEI users. On the contrary, the LACE cohort study reported increased risk of recurrence among ACEIs users among early breast cancer patients (HR=1.56; 95%CI=1.02-2.39)31, but no data on use of ARBs was reported. To our knowledge, no study has explored the association between pCR and the use of RAS antagonists in breast cancer patients receiving NST.

There are many biological models to explain possible anti-tumor or anti-angiogenic effects of RAS antagonists in cell line and animal xenograft models2-8. A favorable effect of ARBs in our study may be explained by these properties. However, the consequence of long term suppression of RAS may cause unintended detrimental side effects such as up-regulation of the angiotensin receptors or related downstream pathway molecules. ACEI and ARB may differ in this paradoxical phenomenon. This may, in part, explain the fact that ACEI only use was not favorably associated with any clinical outcomes in our study and also may explain why an increased risk of recurrence with the ACEI use was found in the LACE study. Of note, ARB use was reported to be associated with increase in overall cancer incidence32, although this has not been validated in subsequently published studies33-36.

There are some limitations to our study. Although our database was built prospectively, our study is prone to the bias inherent to a retrospective design and we cannot rule out residual confounding by unidentified clinical variables non-randomly distributed between the groups compared. We evaluated the use of ACEI/ARBs prescribed concurrently with NST. We have no data available on the use of these drugs after the definitive breast surgery. We could not evaluate medication compliance. Also, our medication data is solely based on medical records, not verified by outside pharmacy records. It is possible that differences in outcome were diluted by differences in adjuvant treatment including radiation, trastuzumab, and endocrine therapy. However, there is no reason to believe that misclassification, residual confounding or lost-to-follow up occurred in a differential manner between ACEI/ARB and non- ACEI/ARB group.

Our findings are based on one of the largest available breast cancer neoadjuvant chemotherapy databases. Clinical information was collected in a prospective way and all patients were treated in a single institution with relatively homogenous chemotherapeutic regimens and surgical and radiation treatments. We were able to account for most known clinical variables that may affect clinical outcome when assessing the effect of ACEI/ARBs in breast cancer patients receiving NST. We also controlled for metformin and beta-blocker use as we previously demonstrated an association between them and pCR and OS, respectively24, 26, although other mediation data including aspirin has not been collected37.

In summary, this study provides the first report that ACEI/ARB use during NST is not associated with pCR rates in breast cancer patients receiving antracyline-and taxane-based NST. However, we found that ARB use, not ACEI, may be linked with favorable RFS. Given the fact that a number of breast cancer survivors with hypertension are on ARBs, this finding harbors vast public health implications and require validation in a larger prospective cohort.